Table 2 Summary of PFS1, PFS2 and PFSratio analysis of precision oncology trials

From: Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials

Study

Median PFS1 (months, 95% CI)

Median PFS2 (months, 95% CI)

Median PFSratio

Weibull distribution

Kendall’s Tau

Proportion of informative cases

SPFSratio(δ=1.3)

WINTHER

4.1 (3.2–5.2)

2.0 (1.8–3.1)

0.74 (0.57–0.83)

no

0.314

106/107 (99%)

0.25 (0.17–0.34)

MASTER

3.2 (3.0–3.7)

3.5 (3.1–4.1)

1.02 (0.86–1.21)

no

0.220

233/255 (91%)

0.41 (0.34–0.47)

MOSCATO 01

3.0 (2.7–3.6)

2.4 (1.9–2.8)

0.75 (0.58–0.92)

no

0.174

193/194 (99%)

0.33 (0.27–0.40)

POG570

3.5 (2.8–4.1)

3.4 (2.5–4.3)

0.81 (0.60–1.01)

no

0.228

152/190 (80%)

0.33 (0.26–0.41)

SHIVA (TPC - > MTA)

2.0 (1.9–.4)

2.3 (2.1–4.1)

1.03 (0.87–1.55)

no

0.295

61/70 (87%)

0.42 (0.29–0.54)

SHIVA (MTA - > TPC)

2.8 (2.1–4.0)

2.3 (1.8–3.2)

0.67 (0.52–1.04)

no

0.354

24/25 (96%)

0.21 (0.08–0.39)

  1. Median PFSratio and SPFSratio(δ=1.3) were calculated using the kernel-based Kaplan Meier method.
  2. CI confidence interval, MTA molecularly targeted agent, PFS progression free survival, PFSratio progression free survival ratio, TPC treatment of physician’s choice, SPFSratio the probability that PFSratio is equal to or greater than δ.
Back to article page